Press Resease

Global Blood Plasma Market - By Distribution Channel (Ambulatory Surgical Centers, Hospitals, And Others), By Application (Coagulation Factor Deficiencies, Hemorrhage, Thrombotic Thrombocytopenic Purpura, Liver Disease, And Other Plasma Applications), And By Region- Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019 – 2025

Published Date: 10-Dec-2020 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-2959 Status : Published

Global Blood Plasma market, which was estimated at about 28.01 (USD Million) in 2018 and is predicted to accrue earnings worth 49.96 (USD Million) by 2025, is set to record a CAGR of nearly about 9.9% over 2019-2025.

Description

The global Blood Plasma market, which was estimated at about 28.01 (USD Million) in 2018 and is predicted to accrue earnings worth 49.96 (USD Million) by 2025, is set to record a CAGR of nearly about 9.9% over 2019-2025. The report offers valuation and analysis of Blood Plasma market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2016 to 2018 along with a forecast from 2019 to 2025 based on value (USD Million).

Introduction

Blood plasma is light-yellowish in color or is straw colored and it acts as liquid base for the blood. Apparently, platelets, red blood corpuscles, and leukocytes make up blood plasma. For the record, blood plasma comprise of nearly 91% to 92% of water and about 9% to 8% of solids. Apparently, coagulants present in blood plasma help in clotting of blood. Electrolytes such as sodium, chloride, calcium, and potassium in blood plasma assist in maintaining the blood pH proportion.

Furthermore, plasma proteins of blood plasma assist in retaining the colloidal osmotic pressure at nearly 25 mmHg. In addition to this, immunoglobulin present in blood plasma helps in combating various kinds of infections. Precisely, blood plasma is a composite of over seven-hundred proteins and enables proficient body functioning.

Global Blood Plasma Market

Market Growth Drivers

Surge in the occurrence of life-threatening disorders like hemophilia is anticipated to create lucrative growth avenues for the market over the projected timespan. Additionally, rise in the acceptance of blood plasma derived products along with a prominent surge in the aging populace prone to liver disorders will culminate in huge demand for blood plasma in the medical industry over the forecast timespan. Apart from this, a large number of benefits offered by blood plasma like coagulation of blood, defense, nutrition, maintaining of osmotic pressure, respiration, excretion, regulating of acid-base balance, and controlling body temperature has transformed into huge market demand in the current years.

Furthermore, blood plasma helps in controlling blood pressure in the human being. Rise in the health problems as a result of altering lifestyles, increase in the fund allocation to healthcare sector, and growing penetration of plasma-derived items in the healthcare industry will create lucrative growth avenues for the industry over the estimated timeline. Nonetheless, high plasma derivative treatment costs as well as post-operative risks related to plasma replacement treatment will put brakes on the industry growth over the forecast timespan.

North American Market To Witness Mammoth Growth By 2026

The expansion of the industry in the sub-continent over the projected timeline is due to massive patient population base in the countries like the U.S. that is affected due to blood coagulation, hemostasis, and hemorrhage. Additionally, new initiatives introduced by the government for creating awareness about the significance of blood donation will proliferate the regional market expansion in the years ahead. In addition to this, occurrence of chronic disorders like heart ailments and cancer will promote the expansion of blood plasma industry in North America over the assessment timeline.

Key participants profiled in the study include Grifols S.A., Kedrion S.p.A., Octopharma AG, Baxter International Inc., CSL Ltd., Biotest AG, Shire, China Biologic Products, and Sanquin.

The global blood plasma market is segmented as follows:

By Application

  • Coagulation factor deficiencies
  • Thrombotic thrombocytopenic purpura
  • Hemorrhage
  • Liver disease
  • Other plasma applications

By Distribution Channel

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodulogy
      • 1.3.1. Market Research Type
      • 1.3.2. Market Research Methodulogy
  • Chapter 2. Executive Summary
    • 2.1. Blood Plasma Market , 2015–2025 (USD Million)
    • 2.2. Blood Plasma Market : Snapshot
  • Chapter 3. Global Blood Plasma Market – Industry Analysis
    • 3.1. Blood Plasma Market : Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Rise in the health problems as a result of altering lifestyles, increase in the fund allocation to healthcare sector, and growing penetration of plasma-derived items in the healthcare industry will create lucrative growth avenues for the industry over the estimated timeline.
      • 3.2.2. A large number of benefits offered by blood plasma like coagulation of blood, defense, nutrition, maintaining of osmotic pressure, respiration, excretion, regulating of acid-base balance, and contrulling body temperature has transformed into huge market demand in the current years.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Application
      • 3.4.2. Market attractiveness analysis By Distribution Channel
  • Chapter 4. Global Blood Plasma Market – Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Blood Plasma Market : company market share, 2017
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Blood Plasma Market – Application Analysis
    • 5.1. Global Blood Plasma Market overview: By Application
      • 5.1.1. Global Blood Plasma Market share, By Application, 2018 and 2025
    • 5.2. Coagulation factor deficiencies
      • 5.2.1. Global Blood Plasma Market By Coagulation factor deficiencies, 2015–2025 (USD Million)
    • 5.3. Thrombotic thrombocytopenic purpura
      • 5.3.1. Global Blood Plasma Market By Thrombotic thrombocytopenic purpura, 2015–2025 (USD Million)
    • 5.4. Hemorrhage
      • 5.4.1. Global Blood Plasma Market By Hemorrhage, 2015–2025 (USD Million)
    • 5.5. Liver disease
      • 5.5.1. Global Blood Plasma Market By Liver disease, 2015–2025 (USD Million)
    • 5.6. Other plasma applications
      • 5.6.1. Global Blood Plasma Market By Other plasma applications, 2015–2025 (USD Million)
  • Chapter 6. Global Blood Plasma Market – Distribution Channel Analysis
    • 6.1. Global Blood Plasma Market overview: By Distribution Channel
      • 6.1.1. Global Blood Plasma Market share, By Distribution Channel , 2018 and 2025
    • 6.2. Hospitals
      • 6.2.1. Global Blood Plasma Market By Hospitals, 2015–2025 (USD Million)
    • 6.3. Ambulatory Surgical Centers
      • 6.3.1. Global Blood Plasma Market By Ambulatory Surgical Centers, 2015–2025 (USD Million)
    • 6.4. Others
      • 6.4.1. Global Blood Plasma Market By Others, 2015–2025 (USD Million)
  • Chapter 7. Company Profiles
    • 7.1. Medivators Inc. (Cantel Medical Corp.)
      • 7.1.1. Overview
      • 7.1.2. Financials
      • 7.1.3. Product Portfulio
      • 7.1.4. Business Strategy
      • 7.1.5. Recent Developments
    • 7.2. Olympus Corporation
      • 7.2.1. Overview
      • 7.2.2. Financials
      • 7.2.3. Product Portfulio
      • 7.2.4. Business Strategy
      • 7.2.5. Recent Developments
    • 7.3. STERIS Plc.
      • 7.3.1. Overview
      • 7.3.2. Financials
      • 7.3.3. Product Portfulio
      • 7.3.4. Business Strategy
      • 7.3.5. Recent Developments
    • 7.4. Getinge Group
      • 7.4.1. Overview
      • 7.4.2. Financials
      • 7.4.3. Product Portfulio
      • 7.4.4. Business Strategy
      • 7.4.5. Recent Developments
    • 7.5. Steelco S.P.A
      • 7.5.1. Overview
      • 7.5.2. Financials
      • 7.5.3. Product Portfulio
      • 7.5.4. Business Strategy
      • 7.5.5. Recent Development
    • 7.6. Belimed AG (Metall Zug)
      • 7.6.1. Overview
      • 7.6.2. Financials
      • 7.6.3. Product Portfulio
      • 7.6.4. Business Strategy
      • 7.6.5. Recent Development
    • 7.7. F. Hoffmann-La Roche Ltd
      • 7.7.1. Overview
      • 7.7.2. Financials
      • 7.7.3. Product Portfulio
      • 7.7.4. Business Strategy
      • 7.7.5. Recent Development
    • 7.8. Pfizer Inc.
      • 7.8.1. Overview
      • 7.8.2. Financials
      • 7.8.3. Product Portfulio
      • 7.8.4. Business Strategy
      • 7.8.5. Recent Development
    • 7.9. Advanced Sterilization Products Services Inc. (Johnson & Johnson)
      • 7.9.1. Overview
      • 7.9.2. Financials
      • 7.9.3. Product Portfulio
      • 7.9.4. Business Strategy
      • 7.9.5. Recent Development
    • 7.10. Merck & Co., Inc.
      • 7.10.1. Overview
      • 7.10.2. Financials
      • 7.10.3. Product Portfulio
      • 7.10.4. Business Strategy
      • 7.10.5. Recent Development
    • 7.11. Bayer AG
      • 7.11.1. Overview
      • 7.11.2. Financials
      • 7.11.3. Product Portfulio
      • 7.11.4. Business Strategy
      • 7.11.5. Recent Development
    • 7.12. Abbott Laboratories
      • 7.12.1. Overview
      • 7.12.2. Financials
      • 7.12.3. Product Portfulio
      • 7.12.4. Business Strategy
      • 7.12.5. Recent Development
    • 7.13. Dickinson and Company
      • 7.13.1. Overview
      • 7.13.2. Financials
      • 7.13.3. Product Portfulio
      • 7.13.4. Business Strategy
      • 7.13.5. Recent Development
    • 7.14. Alere Inc.
      • 7.14.1. Overview
      • 7.14.2. Financials
      • 7.14.3. Product Portfulio
      • 7.14.4. Business Strategy
      • 7.14.5. Recent Development
    • 7.15. Cantel Medical Corp.
      • 7.15.1. Overview
      • 7.15.2. Financials
      • 7.15.3. Product Portfulio
      • 7.15.4. Business Strategy
      • 7.15.5. Recent Development
    • 7.16. Bemis Company
      • 7.16.1. Overview
      • 7.16.2. Financials
      • 7.16.3. Product Portfulio
      • 7.16.4. Business Strategy
      • 7.16.5. Recent Development
    • 7.17. Crosstex International, Inc.
      • 7.17.1. Overview
      • 7.17.2. Financials
      • 7.17.3. Product Portfulio
      • 7.17.4. Business Strategy
      • 7.17.5. Recent Development
    • 7.18. Covidien plc
      • 7.18.1. Overview
      • 7.18.2. Financials
      • 7.18.3. Product Portfulio
      • 7.18.4. Business Strategy
      • 7.18.5. Recent Development
    • 7.19. Diversey, Inc
      • 7.19.1. Overview
      • 7.19.2. Financials
      • 7.19.3. Product Portfulio
      • 7.19.4. Business Strategy
      • 7.19.5. Recent Development
    • 7.20. Danaher Corp.
      • 7.20.1. Overview
      • 7.20.2. Financials
      • 7.20.3. Product Portfulio
      • 7.20.4. Business Strategy
      • 7.20.5. Recent Development
    • 7.21. MMM Group
      • 7.21.1. Overview
      • 7.21.2. Financials
      • 7.21.3. Product Portfulio
      • 7.21.4. Business Strategy
      • 7.21.5. Recent Development
    • 7.22. Getinge Group
      • 7.22.1. Overview
      • 7.22.2. Financials
      • 7.22.3. Product Portfulio
      • 7.22.4. Business Strategy
      • 7.22.5. Recent Development
    • 7.23. Sealed Air Corp
      • 7.23.1. Overview
      • 7.23.2. Financials
      • 7.23.3. Product Portfulio
      • 7.23.4. Business Strategy
      • 7.23.5. Recent Development
    • 7.24. Purdue Pharma LP
      • 7.24.1. Overview
      • 7.24.2. Financials
      • 7.24.3. Product Portfulio
      • 7.24.4. Business Strategy
      • 7.24.5. Recent Development
    • 7.25. Synergy Health plc
      • 7.25.1. Overview
      • 7.25.2. Financials
      • 7.25.3. Product Portfulio
      • 7.25.4. Business Strategy
      • 7.25.5. Recent Development
    • 7.26. Semperit AG Hulding
      • 7.26.1. Overview
      • 7.26.2. Financials
      • 7.26.3. Product Portfulio
      • 7.26.4. Business Strategy
      • 7.26.5. Recent Development

Methodology


Frequently Asked Questions

Surge in the occurrence of life-threatening disorders like hemophilia is anticipated to create lucrative growth avenues for the market over the projected timespan. Additionally, rise in the acceptance of blood plasma derived products along with a prominent surge in the aging populace prone to liver disorders will culminate in huge demand for blood plasma in the medical industry over the forecast timespan. Apart from this, a large number of benefits offered by blood plasma like coagulation of blood, defense, nutrition, maintaining of osmotic pressure, respiration, excretion, regulating of acid-base balance, and controlling body temperature has transformed into huge market demand in the current years.

Furthermore, blood plasma helps in controlling blood pressure in the human being. Rise in the health problems as a result of altering lifestyles, increase in the fund allocation to healthcare sector, and growing penetration of plasma-derived items in the healthcare industry will create lucrative growth avenues for the industry over the estimated timeline.

According to Zion Market Research report, the global Blood Plasma market, which was estimated at about 28.01 (USD Million) in 2018 and is predicted to accrue earnings worth 49.96 (USD Million) by 2025, is set to record a CAGR of nearly about 9.9% over 2019-2025.

North America is likely to make noteworthy contributions towards overall Blood Plasma Market revenue. The growth of the market in the region over estimated timespan can be ascribed to massive patient population base in the countries like the U.S. that is affected due to blood coagulation, hemostasis, and hemorrhage. Additionally, new initiatives introduced by the government for creating awareness about the significance of blood donation will proliferate the regional market expansion in the years ahead. In addition to this, occurrence of chronic disorders like heart ailments and cancer will promote the expansion of blood plasma industry in North America over the assessment timeline.

The key players profiled in the report include Grifols S.A., Kedrion S.p.A., Octopharma AG, Baxter International Inc., CSL Ltd., Biotest AG, Shire, China Biologic Products, and Sanquin.

}
Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com